Rockwell Medical, Inc. (RMTI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. Rockwell Medical, Inc. is a healthcare company developing, manufacturing, and distributing hemodialysis products, primarily liquid and dry acid/bicarbonate concentrates. The company operates in a single reportable segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| Net Sales | $34,985 |
| Gross Profit | $5,545 |
| Gross Margin | 16% |
| Operating Loss | $(2,709) |
| Net Loss | $(3,007) |
| Diluted EPS | $(0.09) |
| Cash and Cash Equivalents | $12,482 |
| Total Investments (Available-for-Sale) | $5,940 |
| Net Working Capital | $20,700 |
| Long-Term Debt (Term Loan, net) | $8,648 |
| Net Cash Used in Operating Activities | $(1,643) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 28% year-over-year (from $48.5M to $35.0M). This was primarily driven by a $14.6M reduction in sales to major customer DaVita, Inc., as they transition to a new supplier. This was partially offset by price increases and new customer sales.
- Profitability: The company reported a net loss of $3.0M for the six months ended June 30, 2025, compared to a net loss of $1.4M in the same period in 2024. Operating loss widened to $2.7M from $0.8M.
- Customer Concentration: DaVita's share of revenue dropped significantly from 44% in the prior year period to 20% in the current period. Fresenius and Nipro now represent 10% and 9% of revenue, respectively.
- Inventory: Inventory levels decreased from $5.8M to $4.2M, including a $0.2M write-off of Triferic raw materials related to terminated international partnerships.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash, cash equivalents, and investments ($18.4M total) plus net working capital are sufficient to meet operating requirements for at least the next 12 months. The company has $21.1M remaining availability under its At-The-Market (ATM) equity facility.
- Debt Covenant Compliance: The company did not satisfy a revenue covenant under its Loan Agreement with Innovatus in Q2 2025 due to the loss of DaVita business. However, the company remediated this by submitting an updated financial projection accepted by the lender. As of June 30, 2025, the company is in compliance with all covenants.
- Strategic Developments: Rockwell entered a new multi-year product purchase agreement with Innovative Renal Care (IRC) in Q2 2025. Discussions with DaVita regarding potential contract extensions or volume commitments are ongoing but uncertain.
- Risks: Key risks include the continued transition of DaVita to a competitor, the ability to raise additional capital on favorable terms, and global macroeconomic instability. The company is also evaluating the impact of new U.S. tax legislation (P.L. 119-21) enacted in July 2025.
Investor Verification Checklist
- DaVita Transition Status: Verify the finality of DaVita's supplier transition and the potential revenue impact beyond the current quarter.
- Debt Covenant Terms: Review the specific terms of the updated financial projection accepted by Innovatus and the conditions for future compliance.
- ATM Facility Usage: Monitor if the company utilizes the $21.1M ATM facility to fund operations given the operating cash burn.
- New Customer Ramp-Up: Assess the revenue contribution from the new agreement with Innovative Renal Care (IRC) and other new customers to offset DaVita losses.
- Inventory Valuation: Confirm the status of remaining inventory reserves and any further write-offs related to discontinued product lines.